SynthesisFrontiers in oncology2025
Knowledge map of recurrence in tenosynovial giant cell tumor: a bibliometric analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pexidartinib: Current advances in the symptomatic treatment of tenosynovial giant cell tumors.Cancer metastasis reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Tenosynovial Giant Cell Tumor (TGCT) is a rare benign neoplasm originating from the synovium and tendon sheath, and is characterized by a relatively high rate of recurrence following treatment. The present study was designed to identify and analyze 134 publications in this domain, with the aim of providing researchers with a comprehensive overview of the knowledge framework and research hotspots related to TGCT recurrence. Methods: A total of 134 articles concerning TGCT recurrence were retrieved from the Web of Science Core Collection. Bibliometric analysis was applied to examine various characteristics of the literature. VOSviewer and Microsoft Excel were employed to perform visualizations of temporal and geographical distributions, author productivity, thematic classifications, topic evolution, reference networks, and keyword co-occurrence. Results: Among the identified articles, the most frequently cited publication received 123 citations. The University of California was found to be the most influential institution in terms of citation frequency, while the United States ranked first in the number of publications. A steady increase in research activity was observed, particularly between 2021 and 2024. Nicholas Matthew Bernthal was identified as the most prolific author, with eight publications. Keywords indicating major research hotspots included "tenosynovial giant cell tumor," "surgical treatment," "recurrence," "synovectomy," and "radiotherapy." Fourteen articles specifically addressed multimodal treatment strategies, highlighting a critical direction of research in this field. Conclusion: Research on TGCT recurrence has received increasing attention, with particular emphasis on multimodal treatment strategies. Nevertheless, the underlying biological mechanisms remain insufficiently elucidated. Further exploration of these mechanisms is warranted to enable future therapeutic advances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.